

PHARMACEUTICAL 2020

GW PHARMACEUTICALS PLC Rank 37 of 358







RealRate

PHARMACEUTICAL 2020

GW PHARMACEUTICALS PLC Rank 37 of 358

The relative strengths and weaknesses of GW PHARMACEUTICALS PLC are analyzed with respect to the market average, including all of its competitors. We analyzed all variables having an effect on the Economic Capital Ratio.

The greatest strength of GW PHARMACEUTICALS PLC compared to the market average is the variable Net Income, increasing the Economic Capital Ratio by 80% points. The greatest weakness of GW PHARMACEUTICALS PLC is the variable Selling, General and Administrative Expense, reducing the Economic Capital Ratio by 11% points.

The company's Economic Capital Ratio, given in the ranking table, is 240%, being 203% points above the market average of 36%.

Input Variable	Value in 1000 USD
Assets, Current	699,636
Cost of Goods Sold	27,199
Intangible Assets	6,959
Liabilities, Current	117,561
Liabilities, Non-Current	38,654
Other Assets	47,889
Other Compr. Net Income	10,065
Other Expenses	903
Other Liabilities	0
Other Net Income	6,192
Other Revenues	415,449
Property and Equipment	127,765
Research and Development	142,678
Selling, General and Administrative Expense	259,880

Output Variable	Value in 1000 USD
Assets	882,249
Liabilities	156,215
Expenses	430,660
Revenues	415,449
Stockholders Equity	726,034
Net Income	-9,019
Comprehensive Net Income	-3,986
Economic Capital Ratio	240%

